Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study.

Wobrock T, Falkai P, Schneider-Axmann T, Hasan A, Galderisi S, Davidson M, Kahn RS, Derks EM, Boter H, Rybakowski JK, Libiger J, Dollfus S, López-Ibor JJ, Peuskens J, Hranov LG, Gaebel W, Fleischhacker WW; EUFEST study group.

Schizophr Res. 2013 Jun;147(1):132-9. doi: 10.1016/j.schres.2013.03.001. Epub 2013 Mar 26.

PMID:
23537477
[PubMed - indexed for MEDLINE]
2.

Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study.

Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, Rybakowski JK, Libiger J, Dollfus S, López-Ibor JJ, Peuskens J, Hranov LG, Fleischhacker WW; EUFEST group.

Schizophr Res. 2009 Dec;115(2-3):104-14. doi: 10.1016/j.schres.2009.09.022. Epub 2009 Oct 12.

PMID:
19822407
[PubMed - indexed for MEDLINE]
3.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
[PubMed - indexed for MEDLINE]
4.

Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia.

Wobrock T, Sittinger H, Behrendt B, D'Amelio R, Falkai P, Caspari D.

Eur Arch Psychiatry Clin Neurosci. 2007 Jun;257(4):203-10. Epub 2006 Nov 25.

PMID:
17131214
[PubMed - indexed for MEDLINE]
5.

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS.

Am J Psychiatry. 2009 Jun;166(6):675-82. doi: 10.1176/appi.ajp.2008.08060806. Epub 2009 Apr 15. Erratum in: Am J Psychiatry. 2009 Jun;166(6):731.

PMID:
19369319
[PubMed - indexed for MEDLINE]
6.

A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.

Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B.

J Clin Psychiatry. 2007 Mar;68(3):368-79.

PMID:
17388705
[PubMed - indexed for MEDLINE]
7.

First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.

Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS; HGDH Research Group.

Schizophr Res. 2004 Feb 1;66(2-3):125-35.

PMID:
15061244
[PubMed - indexed for MEDLINE]
8.

[Cannabis and schizophrenia: demographic and clinical correlates].

Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olié JP, Lôo H, Krebs MO.

Encephale. 2003 Jan-Feb;29(1):11-7. French.

PMID:
12640322
[PubMed - indexed for MEDLINE]
9.

Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function.

Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM, Franco S.

J Clin Psychiatry. 1991 Jan;52(1):26-30.

PMID:
1671032
[PubMed - indexed for MEDLINE]
10.

Executive function in schizophrenia: influence of substance use disorder history.

Rodriguez-Jimenez R, Bagney A, Martinez-Gras I, Ponce G, Sanchez-Morla EM, Aragües M, Rubio G, Jimenez-Arriero MA, Santos JL, Palomo T; PARG.

Schizophr Res. 2010 May;118(1-3):34-40. doi: 10.1016/j.schres.2009.09.025. Epub 2009 Oct 25.

PMID:
19854622
[PubMed - indexed for MEDLINE]
11.

[Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].

Liraud F, Verdoux H.

Encephale. 2002 Mar-Apr;28(2):160-8. French.

PMID:
11972143
[PubMed - indexed for MEDLINE]
12.

Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis.

Potvin S, Joyal CC, Pelletier J, Stip E.

Schizophr Res. 2008 Mar;100(1-3):242-51. Epub 2007 Jul 5.

PMID:
17614260
[PubMed - indexed for MEDLINE]
13.

Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.

Smith RC, Jin H, Li C, Bark N, Shekhar A, Dwivedi S, Mortiere C, Lohr J, Hu Q, Davis JM.

Schizophr Res. 2013 Jan;143(1):18-24. doi: 10.1016/j.schres.2012.10.023. Epub 2012 Nov 29.

PMID:
23200554
[PubMed - indexed for MEDLINE]
14.

Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.

Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.

CNS Drugs. 2013 Jan;27(1):57-65. doi: 10.1007/s40263-012-0022-1.

PMID:
23233269
[PubMed - indexed for MEDLINE]
15.

[Factors related to suicide attempts in a Tunisian sample of patients with schizophrenia].

Bouhlel S, M'solly M, Benhawala S, Jones Y, El-Hechmi Z.

Encephale. 2013 Feb;39(1):6-12. doi: 10.1016/j.encep.2012.06.003. Epub 2012 Sep 25. French.

PMID:
23095582
[PubMed - indexed for MEDLINE]
16.

Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis.

Mata I, Rodríguez-Sánchez JM, Pelayo-Terán JM, Pérez-Iglesias R, González-Blanch C, Ramírez-Bonilla M, Martínez-García O, Vázquez-Barquero JL, Crespo-Facorro B.

Psychol Med. 2008 Sep;38(9):1257-66. Epub 2007 Nov 16.

PMID:
18005495
[PubMed - indexed for MEDLINE]
17.

Psychopathology and Wisconsin Card Sorting Test performance in male schizophrenic patients: influence of dual diagnosis.

Rodriguez-Jimenez R, Aragües M, Jimenez-Arriero MA, Ponce G, Martinez I, Hoenicka J, Rubio G, Palomo T; Psychosis and Addictions Research Group (PARG).

Psychopathology. 2008;41(1):58-64. Epub 2007 Nov 1.

PMID:
17975329
[PubMed - indexed for MEDLINE]
18.

The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.

Good KP, Rabinowitz J, Whitehorn D, Harvey PD, DeSmedt G, Kopala LC.

Schizophr Res. 2004 May 1;68(1):11-9.

PMID:
15037335
[PubMed - indexed for MEDLINE]
19.

Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.

Kim SW, Shin IS, Kim JM, Lee SH, Lee YH, Yang SJ, Yoon JS.

Hum Psychopharmacol. 2009 Oct;24(7):565-73. doi: 10.1002/hup.1057.

PMID:
19790174
[PubMed - indexed for MEDLINE]
20.

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70. Epub 2007 Jul 14.

PMID:
17629731
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk